Partner Site Heidelberg/Mannheim

Prof. Dr. Norbert Frey
Partner site spokesperson
(Heidelberg University Hospital) 

Prof. Dr. Jörg Heineke
Deputy partner site speaker
(University Hospital Mannheim)

Prof. Dr. Johannes Backs
Deputy partner site spokesperson
(Heidelberg University Hospital)

Dr. Tanja Weis
Partner site manager
(Heidelberg University Hospital)
phone: +49 6221 56-38064

Project manager:
Denise Kampffmeyer 
phone: 06221-56-37971

Principal Investigators

Open table

Profile of Partner Site

The DZHK partner site Heidelberg/Mannheim conducts research under the title “Heidelberg University Research Center for Cardiomyopathies and Arrhythmias – From Genes to Translation”, focusing on the causes, signalling pathways and unanswered clinical questions concerning cardiomyopathies. 

The Heidelberg/Mannheim partner site integrates researchers with interdisciplinary experience –clinicians, molecular biologists, geneticists and bioinformaticists of the university hospitals in Heidelberg and Mannheim, Heidelberg University as well as the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL). The DZHK partner site Heidelberg/Mannheim participates in most of the DZHK programmes, however its main focus is on studying cardiomyopathies and arrhythmias within Programme 2 (Hereditary and Inflammatory Heart Disease). The objective of this program is to carry out extensive translational research on cardiomyopathies in order to develop new diagnostic methods and innovative treatment concepts. The research strategy includes techniques of genetic and epigenetic analysis as well as diagnostic imaging and model systems for the functional analysis of molecular signalling pathways, e.g. the zebrafish, mouse, rat and also the pig as human-relevant model. Furthermore, personalised, pluripotent stem cells in the animal model and also from patients will be generated and investigated. From stem cells – initially in the animal model – functional myocardial tissue to repair the diseased tissue will be differentiated (engineered heart tissue). A key objective is also to make the methodology platforms established at the partner site available to all partners in the DZHK. These are the Next Generation Sequencing Platform, the AAV Platform, the Zebrafish Platform, the Large Animal Platform and the Patch Clamp Facility. As an important new infrastructure, a registry for cardiomyopathy patients will be established at the Heidelberg/Mannheim partner site. The objective is to collect extensive clinical data and biomaterial information on many thousands of patients over the long term and to make this available for innovative clinical studies and analyses.